Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports

Wegovy was found to cut the risk of serious heart events by 20%—Novo Nordisk has now asked the U.S. FDA to reflect the heart benefits in the drug's label.

Fortune

Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds

A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients

The Independent UK

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca makes big push into weight-loss market with obesity pill deal

UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill

The Guardian - UK

How a 'Rule of Two' could remove our barrier to better drug access

We need to address the unnecessary and wasteful Medsafe approval for tried and tested drugs by much bigger regulatory authorities abroad, argues Dr Eric Crampton

Newsroom.co.nz

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk's CEO doesn't like proposed new EU rules that would cut the period for which drugmakers enjoy exclusivity for their products from 10 years to eight years.

Fortune

Ozempic's rebranded weight-loss drug should be available next year

'This is real and these medications are here to stay.'

Newcastle Herald

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk gives foodmakers $900 million reason to worry

Sales would have been higher if not for a shortfall following surging demand.

Fortune

Sales soar at Danish firm behind weight-loss drug semaglutide

Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company

The Guardian - UK

3 'Strong Buy' Dividend Stocks That Are Beating the Market

Here are three top-rated dividend stocks that have outperformed the S&P 500 in the past month, despite a tough environment for equities.

Barchart

Warning as patients hospitalised after taking fake Ozempic weight-loss drug

Hundreds of fake Ozempic jabs from the black market have been seied by the regulator

The Independent UK

3 Top-Rated Growth Stocks To Buy on Every Dip

Growth stocks are down, but don't count them out. Here are three top-rated names worth scooping up when the market pulls back.

Barchart

Fears over black market weight loss drugs as people left seriously ill from counterfeit Ozempic

Austria’s criminal investigation service warned on Monday that fake injection pens may still be in circulation

The Independent UK

Aust shares close a smidge higher to extend win streak

The local share market has technically extended its winning streak to six days, with seven of the ASX's 11 sectors finishing in the green.

AAP

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Wall Street is now betting against restaurant stocks because of Novo Nordisk’s Ozempic and high interest rates

Short positions on companies such as McDonald’s and Starbucks have increased in the last month, and weight loss drugs are part of the reason why.

Salon

Rare Ozempic side effects emerging

Though side effects from Ozempic are rare, as usage rises some side effects are becoming more apparent

The Independent UK

Warning over ‘severe’ weight-loss jab side effects

Semaglutide and liraglutide are sold under the brand names Wegovy, Ozempic, Rybelsus and Saxenda and are manufactured by Novo Nordisk

The Independent UK

Weight-loss jabs linked to ‘severe’ stomach problems – study

Researchers said instances were ‘rare’ but hundreds of thousands of people could still be affected due to the drugs’ popularity globally.

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Weight loss-aiding drugs Ozempic and Wegovy are dampening food sales, top Walmart exec says

The drugs, although not officially approved for use in weight loss, have been touted as a “miracle” treatments for obesity.

Fortune

Weight-loss drugs like Ozempic have so much promise a major bank is telling investors to short junk food stocks

Barclays strategists expect "disruption into a number of industries," thanks to drugs like Novo Nordisk's Ozempic and Wegovy.

The Independent UK

Wegovy weight-loss jab 'significantly' improves blood sugar in diabetics

Hailed as potential ‘game changer’ in tackling obesity, Semaglutide can also help those with type 2 diabetes

Fortune

Ozempic and Wegovy ‘significantly’ improve blood sugar and weight for the long-term, new study suggests

The study represents the first long-term, large-scale, real-world trial of the blockbuster drug, researchers said.

The Independent UK

Weight loss jab ‘significantly’ improves blood sugar in diabetics, study finds

Researchers said semaglutide’s effectiveness in treating type 2 diabetes has been shown in some trials, but long-term data is ‘lacking’.

The Independent UK

Denmark's Novo Nordisk and South Africa's Aspen sign a deal to produce insulin for African patients

Danish pharmaceutical company Novo Nordisk has signed a deal with South Africa’s Aspen Pharmacare to produce human insulin specifically for diabetes patients in Africa where there is a dire need for the life-saving treatment

StockNews.com

3 Biotechs with Massive Growth Potential

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

1 … 21 22 23 24

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.